Publication Name	World Journal of Gastroenterology
Manuscript ID	114713
Country	China

Category	Oncology
Manuscript Type	Basic Study
Article Title	LGALS1 drives chemoresistance in esophageal squamous cell carcinoma by modulating epithelial-mesenchymal transition and tumor immunity
Manuscript Source	Unsolicited Manuscript
All Author List	Qi-Hang Yan, Chen-Di Xu, Zhen-Guo Li, Yu-Zhen Zheng, Wing-Shing Wong, Da-Chuan Liang, Jie Yang, Wu-Guang Chang and Jun-Ye Wang
Funding Agency and Grant Number	Funding Agency Grant Number National Natural Science Foundation of China No. 82173293
Corresponding Author	Jun-Ye Wang, MD, Professor, Guangdong Esophageal Cancer Institute, Sun Yat-Sen University Cancer Center, No. 651 Dongfeng East Road, Guangzhou 510060, Guangdong Province, China. wangjy@sysucc.org.cn
Key Words	Neoadjuvant chemoradiotherapy; Esophageal squamous cell carcinoma; Single-cell RNA sequencing; LGALS1; Cisplatin resistance
Core Tip	In this investigation, we comprehensively characterized the dynamic changes in the immune microenvironment during treatment by analyzing single-cell RNA sequencing data of esophageal squamous cell carcinoma (ESCC) patients who underwent neoadjuvant chemoradiotherapy. LGALS1 was found to be a gene associated with neoadjuvant chemoradiotherapy resistance in ESCC. Subsequent experimental validation demonstrated LGALS1’s contribution to cisplatin resistance in ESCC through both in vitro and in vivo investigations. These studies illustrate ESCC cisplatin drug treatment failure mechanisms, emphasized the LGALS1 can serve as a promising therapeutic target. It also reveals a potential strategy to overcome the development of cisplatin resistance in ESCC, laying a foundation for the development of more effective individualized treatment regimens, and potentially leading to better outcomes for patients with advanced esophageal cancer.
Citation	Yan QH, Xu CD, Li ZG, Zheng YZ, Wong WS, Liang DC, Yang J, Chang WG, Wang JY. LGALS1 drives chemoresistance in esophageal squamous cell carcinoma by modulating epithelial-mesenchymal transition and tumor immunity. World J Gastroenterol 2026; In press

Received	2025-11-18 09:34
Peer-Review Started	2025-11-18 09:34
First Decision by Editorial Office Director	2025-12-05 07:13
Return for Revision	2025-12-05 07:13
Revised	2025-12-18 12:50
Publication Fee Transferred	2025-12-24 02:55
Second Decision by Editor	2026-01-27 02:37
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2026-01-27 08:00
Articles in Press	2026-01-27 08:00
Edit the Manuscript by Language Editor
Typeset the Manuscript

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com